Le Lézard
Classified in: Science and technology, Business, Covid-19 virus
Subject: CXP

Vyopta Accelerates Growth as Video and Unified Communications are now Critical


AUSTIN, Texas, July 14, 2020 /PRNewswire/ -- Vyopta, the leading provider of UC monitoring and analytics, today announced significant growth in revenue, customers, talent, and product innovation since it announced $7.5 million in funding from Elsewhere Partners in 2019. As enterprises around the world dramatically increased the use of UC as a Service (UCaaS), especially video conferencing, to collaborate, Vyopta's sales grew by over 60% year over year in Q2 2020.

The company expanded its team in several key areas and added leading Fortune 500 and Global 2000 companies to its customer base. Vyopta also rolled out many major product and platform enhancements, expanded coverage of major UC vendors, including Zoom, Microsoft, Cisco, BlueJeans by Verizon, Pexip, and more.

"The coronavirus crisis has accelerated the adoption of remote work, telemedicine, and distance learning," said Alfredo Ramirez, CEO of Vyopta. "For the first time, CEOs and other C-Suite executives need to ensure that UC technology is being proactively monitored and managed in order to attain planned business outcomes."

Customer and Team Growth
Enterprises and large organizations gravitated to Vyopta to optimize UC across multiple platforms. In the past year, many of the world's largest organizations started using Vyopta and the company counts over 70 of the Global 2000 and over 30 of the Fortune 500 as customers. Some of Vyopta's key customer industries include finance, federal government, technology, healthcare, education, and pharmaceutical, including several enterprises pursuing a vaccine for Covid-19.

Vyopta invested in strategic hiring growth over the past 12 months, with a focus on Customer Success, Sales, and Marketing. Dan Rourke, who previously held leadership positions at Spredfast (now Khoros) and HomeAway (now Expedia) joined the company as Vice President of Customer Success and tripled the size of that team. The company also hired Spiceworks (now Spiceworks Ziff Davis) veteran Jonathan Sass to lead the Product Management organization.

Product Innovation
Key product enhancements over the past 12 months include:

About Vyopta Incorporated
Vyopta is a leading provider of Collaboration Performance Management and meeting room insights solutions. With coverage that spans video, voice, and messaging from Zoom, Microsoft, Cisco, Pexip, BlueJeans by Verizon, Slack, Google, Poly and more, Vyopta helps companies improve quality of experience, accelerate workplace transformation and optimize investments across UC and conference rooms. Vyopta monitors and analyzes over 10 billion meeting minutes annually across the largest enterprises in the world, including Workday, AstraZeneca, Stanford University, Shared Services Canada and the U.S. Department of Veterans Affairs.

SOURCE Vyopta Inc


These press releases may also interest you

at 01:20
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIOŽ (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: